for taxadiene synthase 16 . The cell pellet (19 g) was suspended in 30 mL of buffer E (50 mM K 2 HPO 4 (pH 7.5), 300 mM NaCl, 10% (v/v) glycerol, 3 mM β-mercaptoethanol) containing 1 mg/mL lysozyme and 1 mM phenylmethylsulfonyl fluoride, then incubated at 4°C for 2 h with shaking. Cells were disrupted by sonication on ice with a large probe at medium power, 10 × (30 s on + 30 s off). Cell debris was cleared by centrifugation twice at 30,000g for 1 h. The clear supernatant was applied to a pre-equilibrated Ni-NTA column (QIAGEN, USA) at a flow rate of 1 mL/min using an ÄKTAprime plus FPLC system (GE Healthcare Bio-Sciences AB, Sweden).
The loaded column was washed 3 times with 3 column volumes of first buffer E, then buffer E plus 2 mM imidazole, then buffer E plus 4 mM imidazole. The CPS protein was eluted with a gradient of 8-500 mM imidazole in buffer E at a flow rate of 2.5 mL/min. Selected fractions were combined, concentrated to a volume of 5 mL, and purified by gel-filtration chromatography as previously described for taxadiene synthase 16 . CPS was concentrated to a maximum of 5 mg/mL and the sample purity was 99% based on SDS-PAGE analysis. were used as described in the supplier's guidelines for co-crystallization of the CPS-1 and CPS-2 complexes, respectively. Crystals were flash-cooled after transfer to a cryoprotectant solution consisting of the mother liquor augmented with 10% glycerol.
X-ray diffraction data collection and processing. Crystals of the CPS-1 complex and the CPS- Phasing and structure refinement. (271) 140 (284) 1.5 3.3 3.3 *Number of residues in aligned domains is given in parentheses. TXS = taxadiene synthase, PDB 3P5R; SHC = squalene-hopene cyclase, PDB 1SQC; OSC = oxidosqualene cyclase, PDB 1WK6. 
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